Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Atai Life Sciences N.V. (ATAI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.33

-0.09 (-6.34%)

At close: Jan 14, 2025, 3:59 PM

1.33

0.02%

After-hours Jan 14, 2025, 07:59 PM EST

undefined% (undefined)

Bid	1.32
Market Cap	223.13M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.8
PE Ratio (ttm)	-1.66
Forward PE	n/a
Analyst	Buy

Ask	1.33
Volume	1,263,111
Avg. Volume (20D)	1,711,508
Open	1.43
Previous Close	1.42
Day's Range	1.30 - 1.43
52-Week Range	1.03 - 2.85
Beta	undefined

About ATAI

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modul...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 18, 2021

Employees 83

Stock Exchange NASDAQ

Ticker Symbol ATAI

Website https://www.atai.life

Analyst Forecast

According to 4 analyst ratings, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 652.05% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Atai Life Sciences N.V. is scheduled to release its earnings on Mar 27, 2025, before market opens.
Analysts project revenue of $250.00K, reflecting a 1.29K% YoY growth and earnings per share of -0.15, making a 25.00% increase YoY.

Why Price Moved

7 months ago · Source

-8.44%

Shares of psychedelics companies are trading lower... Unlock content with Pro Subscription

9 months ago · Source

+27.81%

ATAI Life Sciences shares are trading higher after Maxim Group upgraded the stock from Hold to Buy and announced a $6 price target.

News

4 days ago · proactiveinvestors.com

atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health therapies. Dr Srinivas Rao has officially transiti...

2 months ago · proactiveinvestors.com

atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies...

2 months ago · proactiveinvestors.com

atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01

atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the U...

2 months ago · proactiveinvestors.com

RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say

President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented supp...